Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncternal Therapeutics Inc reports Q1 loss but advances promising therapies

Oncternal Therapeutics Inc's Q1 2024 performance reflects ongoing investment in innovative therapies amidst a net loss of $8.4 million.
The company's financial stability, upcoming milestones, and engagement with analysts position it well for future growth and development.
Challenges in managing expenses, meeting clinical data timelines, and ensuring therapeutic success underscore the need for strategic decision-making and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's third quarter financial results.

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal's next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534, which is currently under investigation in an ongoing Phase 1/2 clinical study, ONCT-534-101.

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company's dual-action androgen receptor inhibitor.

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534.

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer & Company Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.

Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.23 per share a year ago.

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates

SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2023 financial results.

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets close on Thursday, August 10, 2023. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's second quarter financial results.

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs). The letter was received prior to the 30-day review date.

Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-808, the company's ROR1 targeting autologous CAR T cell therapy.

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal's President and Chief Executive Officer will present at the 2023 Jefferies Healthcare Conference.

Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrnes - Northland Capital Markets Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to the Oncternal Therapeutics First Quarter 2023 Financial Results Call. [Operator Instructions] As a reminder, this conference will be recorded.

Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call Transcript

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2023 financial results.

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 4, 2023. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results

Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Bright Minds Biosciences

Genprex

Heliogen

Inovio Pharmaceuticals

mCloud Technologies Corp

National CineMedia

NeuroBo Pharmaceuticals Inc

Predictive Oncology Inc

Vascular Biogenics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 10 Under $1 To Watch This Week

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 Under $1 To Watch This Week

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer & Co.'s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m. EDT.

Oncternal Therapeutics Participating in Oppenheimer & Co.'s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors

Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.

Oncternal (ONCT) Down on Restructuring Plan to Extend Runway

Oncternal Therapeutics (NASDAQ: ONCT ) stock is falling hard on Tuesday after the company decided to end two clinical trials. Oncternal Therapeutics has announced that it's closing its Zilovertamab Phase 3 Study ZILO-301 and its Phase 1/2 Study CIRM-0001 study.

Why Is Oncternal Therapeutics (ONCT) Stock Down 62% Today?

SAN DIEGO, April 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced a strategic reprioritization based on the rapidly changing commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors). The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025. The projected cash runway will support the clinical advancement of our two pipeline assets ONCT-808 and ONCT-534.

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants James Breitmeyer - President and CEO Richard Vincent - CFO Salim Yazji - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrnes - Northland Capital Markets Operator Greetings and welcome to the Oncternal Therapeutics, Inc. Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Call Transcript

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2022 financial results.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2022 financial results after the U.S. financial markets close on Thursday, March 9, 2023. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

News for Oncternal Therapeutics Inc Stock (ONCT)